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Background: Switching primary/secondary immunodeficiency (PID/SID) patients from intravenous immunoglobulin
(IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy reduces nurse time. A nurse shortage in Canada
provides an important context to estimate the net economic benefit, the number of patients needed to switch to SCIg
to recoup one full-time equivalent (FTE), and potential population-wide savings of reduced nurse time to a payer.
Methods: The net economic benefit was estimated by multiplying the hourly compensation for nurses in Canada by
the hours required for each administration route. The number needed to switch to SCIg to gain one nurse FTE was
estimated by dividing the work hours in a year by the average annual savings in nursing time in a PID population in
Canada. The prevalence of treated PID/SID in Canada was calculated using provincial IgG audit data to extrapolate the
potential population-wide savings of switching patients to SCIg therapy.
Findings: The net economic gain from switching one patient to home-based SCIg care would be C$2,603 (Canadian
Dollars) in year 1 and C$2,948 each year thereafter. Switching 37 IVIg patients to SCIg would gain one nurse FTE.
Switching 50% of the estimated 5,486 PID and SID patients in Canada receiving IVIg therapy to SCIg has the potential
to save 223.3 nurse FTEs (C$23.2 million in labor costs).
Conclusions: A shift from IVIg to less labor-intensive SCIg has the potential to help alleviate nurse shortages and
reduce overall health care costs in Canada. Health care professionals might consider advocating for home-based SCIg
therapy for PID/SID patients when clinically appropriate.
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Canada has a shortage of registered nurses (RNs), pre-
dicted to increase to almost 60,000 full-time equivalents
(FTEs) by 2022. [1] Professionals in the field suggest the
national demand for nurses is masked by delayed retire-
ments and heavy workloads. [2] Public-sector health-care
nurses worked 21.54 million hours of paid and unpaid* Correspondence: gerthw@verizon.net
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unless otherwise stated.overtime in 2012 equal to 11,900 FTE jobs at a cost of
C$925.5 million annually [3]. Strong links have been found
in Canada between medication errors and the nurses’
workplace environment including working overtime, role
overload, and perceived staffing shortages [4]. Increasing
RN productivity by one percent per year would reduce the
nurse shortage by nearly 50% by 2022 [1] and has the
potential to cut nurse overtime.
Demand for hospital and office-based intravenous in-
fusion therapy will grow with an aging demographic.
Canadian Blood Services (CBS) reports 8.3% annual growth
in overall immune globulin usage from 2006/07 to 2010/td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ceiving IVIg grew by 42.6% from 2003/04 to 2008/09 with
PID/SID comprising 39.3% of total usage [6]. Infusion
therapy is required in many other medical conditions in-
cluding cancer, gastrointestinal diseases, and diseases re-
quiring specialty infusion therapies like congestive heart
failure and rheumatoid arthritis. Capacity to provide care
to these patients will need to increase in terms of facilities
and staffing.
SCIg replacement provides acceptable immunoglobu-
lin (IgG) trough levels, a low incidence of side effects,
similar efficacy to IVIg infusions, and faster functional
recovery with less time off work in the treatment of PID
[7]. There is evidence from North America that health-
related quality of life and treatment satisfaction are
improved when patients receiving IVIg are switched
to home-based SCIg [8].
A recent report suggests that a key to slowing the
growth of health spending is unlocking innovation to
reduce the labor-intensity of care [9]. Home-based SCIg
appears to provide a less labor-intensive means of care
than hospital/office-based IVIg. In one Canadian study
by Ducruet et al., the time spent by nurses in a PID
pediatric center was 52.5 hours less per year with SCIg
relative to IVIg, resulting primarily from a shift in watch-
ing over patients receiving IVIg to teaching patients to
administer their SCIg. First year costs related to the
nurse, technician and administration time were C$1,594
lower in patients switched from IVIg to SCIg (33.2% of
overall C$4,801 savings with SCIg) [10]. In another
Canadian study of adult PID by Martin et al., a switch
from IVIg to home-based rapid push SCIg resulted in
45.2 fewer hours of nursing time in the first year post-
switch and 51.2 fewer hours annually thereafter. Healthcare
system costs were reduced by C$5,735 per patient treated
with SCIg over three years compared to IVIg, principally
because of less use of hospital nursing personnel [11].
These studies did not explore the trade-offs and variability
payers across Canada may face in the efficient allocation of
nurse staff around delivery of IgG to PID/SID patients.
The aim of this paper is to estimate the economic ad-
vantages from a payer perspective in Canada specifically
from reduced nurse time patients with PID/SID who switch
from hospital-based IVIg to home-based SCIg therapy.
Methods
Three modeling approaches were taken to estimate the
economic benefits of reduced nurse time from switching
PID/SID patients from IVIg to SCIg: assessing the net
economic benefit on short-term demands of nurse train-
ing to safely facilitate a switch; assessing the number of
PID/SID patients needed to switch to gain one nurse
FTE; and, assessing the population-wide savings potential
across Canada.Net economic benefit
The cost in nursing time to educate and monitor the
switching patients receiving IVIg to SCIg, and the sav-
ings from that expenditure, was estimated by multiplying
the number of nursing hours and related labor costs in
year 1 and in subsequent years for each route of adminis-
tration. Nurse time estimates from Martin et al., of 45.2
and 51.2 fewer hours of nurse time in the first and an-
nually in subsequent years post-switch to SCIg, were used
in the base-case analysis. SCIg administration required
12 hours of RN time in year 1 (training 6, follow-up visits
6 hours) and 6 hours of RN time for follow-up visits in
each subsequent year. IVIg required 57.2 hours of RN
time each year assuming 14.3 visits per patient annually
(two-thirds 13, one-third 17 visits) and a 4-hour infusion
session each visit.
Hourly nurse compensation (C$57.58) was estimated
by dividing the average annual wages and benefits of
C$104,400 for one full time general duty nurse in British
Columbia in 2011 [12] by the number of hours in a
work year. The hours worked in a typical year was set at
1,813 hours (37-hour workweek; 49 work weeks) [3].
Hourly nurse compensation was multiplied by the hours
required for each route of administration to estimate the
net economic benefit in switching to SCIg. Estimates are
provided on a per patient switched basis and per the num-
ber of patients needed to switch to recoup one nurse FTE.
Number needed to switch (NNS)
The number of PID/SID patients needed to switch to re-
duce one nurse FTE was estimated by dividing the hours
worked in a year (1,813) by the 49.2 hours in average
annual savings in nurse time over three years (used to
smooth out and take into account the increase in savings
from 45.2 hours in year 1 to 51.2 annually thereafter).
Population-wide savings potential
The population-wide savings potential in terms of nursing
hours, FTEs and labor costs was estimated for Canada
assuming 50% to 75% of currently treated patients are
switched.
The prevalence of IgG treated PID/SID patients needed
to be generated to anchor the population-wide savings
potential since there are no population wide estimates
of treated PID or SID (treated or untreated) patients in
Canada. Martin et al. report there were 456 treated PID
patients in BC in 2008/2009 with 4.46 million inhabi-
tants at the time according to Statistics Canada. The
prevalence of treated PID in BC (10.2/100,000) multi-
plied by the 2012 population from Statistics Canada was
used to project the treated PID population to Canada.
The ratio of IgG issued between PID and SID patients
was used to estimate the treated SID population. Utilization
audits by the blood coordinating offices in the Atlantic
Table 1 Annual net economic benefit in Canada: Nurse
time and compensation per patient switched from
hospital-based IVIg to home-based SCIg
Year 1 Subsequent years
Home-based SCIg Therapy
Nurse hours: training 6 0
Nurse hours: monitoring 6 6
Nurse compensation, C$ 691 345
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[6], and Ontario (2007/2008) [14] provided the usage by in-
dication ratios used to estimate the treated SID population.
The IgG usage distributions for PID/SID among all indica-
tions were 17.4%/5.7% in the Atlantic Provinces, 26.1%/
13.2% in BC, and 22.8%/12.9% in Ontario suggesting that
approximately 65% of IgG usage is in PID and 35% in SID
patients. The treated PID prevalence rate was used to esti-
mate IgG treated SID patients in Canada.Hospital-based IVIg therapy
Nurse Hours: IV administration
and monitoring
57.2 57.2
Nurse Compensation, C$ 3,294 3,294
Net economic benefit (IVIg – SCIg)
Savings: nurse hours 45.2 51.2
Savings: nurse compensation, C$ 2,603 2,948Sensitivity analyses
Univariate sensitivity analyses were performed to assess
the robustness of the base-case results. The four param-
eters and the degree to which they were varied follows:
 Hours in Typical Work Year - decreased to 1,656
(36 hours × 46 weeks) to better reflect actual
hours on the job given the number of national
holidays in Canada and increased vacation time
for experienced RNs
 Prevalence of Treated PID - changed to 12.4/
100,000 (199 IgG treated patients) in the Atlantic
Provinces (2011/2012) [13]
 Number of Saved Nursing Hours - increased to
157.5 to reflect saved nursing time from Ducruet
et al. [10]; and, decreased IVIg nurse time by 25% to
128.7 hours over 3 years
 Nurse Compensation - changed bounded by the
provinces with the highest and lowest maximum
annual income for general duty RNs in Canada so
that all provinces are contained within the range
provided: compensation was adjusted upward by
13.4% to capture higher nurse compensation in
Alberta and adjusted downward by 16.2% to capture
lower nurse compensation in Quebec [15].Table 2 Annual net economic benefit in Canada: Nurse
time and compensation per 37 patients switched from
hospital IVIg to home SCIg to recoup 1 nurse FTE
Year 1 Subsequent years
Home-based SCIg therapy
Nurse hours: training 222 0
Nurse hours: monitoring 222 222Findings
Net economic benefit
The expenditure in year 1 for nurse time to switch one
patient to SCIg would be C$691 and C$345 annually
thereafter to offset C$3,294 of hospital-based nursing
time annually (Table 1). The net economic benefit per
patient would be C$2,603 in year 1 and C$2,948 annually
thereafter.Nurse compensation, C$ 25,565 12,783
Hospital-based IVIg therapy
Nurse hours: IV administration
and monitoring
2,116.4 2,116.4
Nurse compensation, C$ 121,862 121,862
Net economic benefit (IVIg – SCIg)
Savings: nurse hours 1,672.4 1,894.4
Savings: nurse compensation, C$ 96,297 109,080Number needed to switch (NNS)
The number of patients that need to switch from IVIg to
SCIg to recoup one nurse FTE is 36.85 (rounded to 37
for subsequent calculations). The net annual savings in
nurse time would be 1,672.4 hours valued at C$96,297
in year 1 and 1,894.4 hours valued at C$109,080 an-
nually thereafter (Table 2).Population-wide savings potential
There are an estimated 5,486 patients with PID/SID
(3,566 PID, 1,920 SID) receiving IVIg in Canada (Table 3).
Switching 50% to 75% of IVIg-treated patients with PID/
SID to SCIg has the potential to save, or free up, 223.3 to
335.1 nurse FTEs, representing C$23.3 to C$35.0 million
in labor costs (Table 4).
Sensitivity analyses
Hours in a typical work year
Changing the work-year hours to 1,656 decreases the
number needed to switch to 33.66 to recapture one nurse
FTE. The hourly cost of labor increases to C$63.04 as the
number of hours in a work year decreases and annual
wages and benefits remain constant. The expenditure in
year 1 for nurse time to switch one patient to SCIg in-
creases to C$756 and C$378 annually thereafter to offset
C$3,606 in hospital-based nursing time annually.
Table 3 Estimated number of IgG-treated patients with





Alberta 3,873.7 396.1 213.3 609.3
British Columbia 4,622.6 472.6 254.5 727.1
Quebec 8,054.8 823.6 443.5 1,267.1
Manitoba 1,267.0 129.5 69.8 199.3
New Brunswick 756.0 77.3 41.6 118.9
Newfoundland
& Labrador
512.7 52.4 28.2 80.7
Nova Scotia 948.7 97.0 52.2 149.2
Ontario 13,505.9 1,380.9 743.6 2,124.5
Prince Edward Island 146.1 14.9 8.0 23.0
Saskatchewan 1,080.0 110.4 59.5 169.9
Territories 113.1 11.6 6.2 17.8
Total 34,880.6 3,566.0 1,920.0 5,486.0
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Increasing the prevalence of treated PID to 12.4/100,000
increases the number of treated PID/SID patients in
Canada to 6,673. Switching 50% to 75% of IVIg patients
to SCIg increases the potential savings to 271.7 to 407.5
nurse FTEs, representing C$28.4 to C$42.5 million in
cost savings.
Number of saved nursing hours
Increasing saved nursing hours to 157.5 over 3 years
would:
 Reduce number needed to switch to 34.53 to recoup
one nurse FTE.Table 4 Estimated 3-year savings (Hours, FTEs, Costs) from sw
from hospital IVIg to home SCIg in Canada by province
Province Savings with 50% switch rate
Hours FTEs Labor costs (C
Alberta 44,969 24.8 $ 2.5
British Columbia 53,662 29.6 $ 3.0
Quebec 93,506 51.6 $ 5.3
Manitoba 14,708 8.1 $ 0.8
New Brunswick 8,776 4.8 $ 0.5
Newfoundland & Labrador 5,952 3.3 $ 0.3
Nova Scotia 11,013 6.1 $ 0.6
Ontario 156,786 86.5 $ 9.0
Prince Edward Island 1,696 0.9 $0.1
Saskatchewan 12,537 6.9 $ 0.7
Territories 1,313 0.7 $ 0.0
Total 404,918 223.3 $ 23.3 Increase potential savings to 238.3 and 357.5 nurse
FTEs, representing an increase in saved labor costs
to C$24.9 and C$37.3 million assuming 50% to 75%
of patients are switched.
Decreasing IVIg nurse time by 25% to 128.7 hours
over 3 years would:
 Increase number needed to switch to 52.0 to recoup
one nurse FTE.
 Decrease potential savings to 158.4 and 237.6 nurse
FTEs, reducing saved labor costs to C$16.5 and
C$24.8 million assuming 50% to 75% of patients
are switched.
Nurse compensation
Increasing wages and benefits by 13.4% to C$118,390
(C$65.30 per hour) increases the net economic benefit
to switch one SCIg patient in year 1 to C$2,952 and annu-
ally in subsequent years to C$3,343. Decreasing wages and
benefits by 16.2% to C$87,487 (C$48.25 per hour) decreases
the net economic benefit in year 1 to C$2,181 and in subse-
quent years to C$2,470 annually.
Discussion
The paper presents three methods to express the eco-
nomic benefits to payers in Canada from nurse time sav-
ings by shifting PID/SID patients from labor-intensive
IVIg to less labor-intensive SCIg. We show that for every
hour or Canadian dollar of nurse time in training and
follow-up of SCIg patients in year 1 that 4.8 hours or
C$ of nurse time for IVIg is offset. This increases to
9.5 hours or C$ annually thereafter. We estimate on a
non-cumulative basis that for every 37 patients switcheditching 50% to 75% of treated patients with PID/SID
Savings with 75% switch rate
$ millions) Hours FTEs Labor costs (C$ millions)
9 67,453 37.2 $ 3.88
9 80,493 44.4 $ 4.64
8 140,258 77.4 $ 8.08
5 22,062 12.2 $ 1.27
1 13,164 7.3 $ 0.76
4 8,928 4.9 $ 0.51
3 16,520 9.1 $ 0.95
3 235,179 129.7 $ 13.54
0 2,544 1.2 $ 0.15
2 18,806 10.4 $ 1.08
8 1,969 1.1 $ 0.11
0 607,376 335.0 $ 34.98
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5,486 PID/SID patients in Canada, between 223.3 to 335.0
FTEs could be redeployed to other service needs over a
3-year timeframe if 50% to 75% of IVIg patients were
switched.
The 7-fold net increase in RN productivity observed in
switching patients to SCIg far exceeds the one percent
needed to reduce nurse shortages 50% by 2022 [1]. The
projected annualized 3-year savings of 223 to 335 nurse
FTEs represents 0.62% to 0.94% of the 11,900 FTEs in
overtime for nurses in 2012 and 0.29% to 0.45% of the
estimated 25,000-nurse shortage in 2013. This contri-
bution would arise from a program that involves just
0.0157% of the Canadian population.
In the short term, nurse labor costs can be viewed as
fixed and unlikely to vary with changes in patient vol-
ume. These costs, however, can be variable over the long
run as nursing staff can be either downsized or upsized
[16]. While opportunities to reallocate freed nursing time
does not immediately reduce expenditures for hospitals,
it has the potential to help manage the pressing demand
for nurse time across the healthcare community in the
short run.
The shift to SCIg in PID/SID patients likely has room
for growth. The 2011/2012 IVIg and SCIg utilization for
the Atlantic Provinces report that 13.5% of their PID pa-
tients have transitioned to self-administered home-based
SCIg [13]. In the case of patients already switched, the
initial investment has been made and the sustained ben-
efits accruing. Considering that 69-81% of PID patients
prefer SCIg to IVIg and 90-92% prefer home therapy, [8]
there is ample opportunity for improved economic bene-
fits to the health care system.
The following limitations are worth noting:
 The nurse time saved may be less than in our
analysis. The 147.6 hours saved in our base-case is
more conservative than the 157.5 hours reported in
a pediatric PID population. We also did not take
into account time saved for other IVIg-related
institution staff (e.g., clerical aids, technicians), the
patient, and family members.
 Patients switched to SCIg may want to switch back
to IVIg and thus reduce the net economic benefit. It
is unlikely that more than 5% of patients will switch
back to IVIg given the preference data from Nicolay
et al. [8].
 The prevalence data on treated PID from BC may
not be generalizable across other provinces in
Canada. The Ontario Intravenous Immune Globulin
(IVIG) 2012 Audit [17] report indicates there are
509 PID patients receiving IVIg compared to our
estimate of 1,381 patients: nearly a 3-fold difference.
This may reflect a real difference in IVIg utilizationbetween Ontario and the other provinces or the
audit methodology.
 The proportion of treated PID/SID patients may
vary from the 65%/35% split in IVIg issues by
indication we used to estimate the prevalence of
treated SID. We may have over/underestimated the
prevalence of treated SID and by extension the
population-wide savings potential of switching this
population from IVIg to SCIg.
 Lastly, the salary-only data from the Canadian
Federation of Nurses Unions in the sensitivity analysis
does not reflect any variability there might be in
benefits nor does it capture provisions for
overtime pay.
The Canadian Institute for Health Information reports
that compensation paid to health care providers is one of
the most significant drivers of public sector health-care
spending. Compensation constitutes 60% of the total hos-
pital costs, and the single largest component of the work-
force in hospitals is nurses [18]. Various Deputy Ministries
of Health (MoH) within a province have a stake in ensur-
ing efficient delivery of healthcare. An increase in nurse
staff for SCIg may require additional funding separate
from that for nurse staff devoted to IVIg. A better under-
standing across functional areas within the MoH of the
offsets in nursing time by switching appropriate PID/SID
patients from IVIg to SCIg may help advance a dialogue
on the resources needed to facilitate these switches.
This paper seeks to clarify advantageous labor eco-
nomics from a payer point of view. It did not attempt to
conduct a full economic analysis of patients switching
from IVIg to SCIg. Such analyses, if conducted, should
benefit from this paper’s contributions.Conclusions
The shift from labor-intensive hospital-based IVIg to less
labor-intensive home-based SCIg therapy has the poten-
tial to reduce overall health care costs borne by payers. In
nations like Canada that have experienced chronic nursing
shortages, the benefits of these patients switching modes
of therapy would help alleviate nurse shortages. Health
care professionals might consider advocating for home-
based SCIg therapy for PID/SID patients when clinically
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